Adocia Announces Half Year Report on Adocia’s Liquidity Agreement With Kepler Capital Markets

Adocia Announces Half Year Report on Adocia's Liquidity Agreement With Kepler Capital Markets

Subscribe

13 Jan 2022 18:00 CET

Regulatory News:

Under the liquidity agreement entrusted by ADOCIA (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account onDecember 31st, 2021:

• Number of shares : 39,816
• Cash balance of the liquidity account: € 65,112.35

During the 2^nd half of 2021, a total of:

Buy side	67,820 shares	€ 614,508.53	528 transactions
Sell side	61,982 shares	€ 579,314.42	303 transactions

The following resources appeared on the last half year statement on June 30, 2021 on the liquidity account:

• Number of shares : 33,978
• Cash balance of the liquidity account: € 100,306.46

The following resources appeared on the liquidity account when the activity started:

• Number of shares : 15,026
• Cash balance of the liquidity account: € 300,000.00

The liquidity agreement complies with AMF Decision n° 2021-01 of June 22nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

About Adocia

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic peptides and proteins for the treatment of diabetes and metabolic diseases. In the diabetes field, Adocia's portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring six clinical-stage products and several pre-clinical products.

Adocia's clinical pipeline includes five novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone^® Lispro U100 and U200), a combination of basal insulin glargine and rapid acting insulin lispro (BioChaperone^® Combo) and two combinations of a prandial insulin with amylin analog pramlintide (M1Pram and BioChaperone^® LisPram). The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone^® Glucagon) for the treatment of hypoglycemia.

Adocia's preclinical pipeline includes bi-hormonal combinations for diabetes treatment: a combination of aspart rapid acting insulin analog and pramlintide (BioChaperone^® AsPram), a combination of insulin glargine with GLP-1 receptor agonist (BioChaperone^® Glargine Liraglutide). In addition, there are three multi-hormonal products for the treatment of obesity: a combination of glucagon and exenatide (BioChaperone^® GluExe), a combination of pramlintide and exenatide (PramExe) and a triple combination of pramlintide glucagon exenatide (BioChaperone^® PramGluExe).

Adocia's portfolio is based on three technology platforms: 1) The BioChaperone^® platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use; 2) A platform designed to improve cell therapy techniques using a hydrogel matrix; 3) A platform for the oral delivery of peptides.

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the "Risk Factors" section of the universal registration document that was filed with the French Autorité des marchés financiers on April 20, 2021 (a copy of which is available at www.adocia.com), in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.

The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause those actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.

This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia's shares in any jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005724/en/

Adocia
Gérard Soula
CEO
[email protected]
Ph: +33 4 72 610 610
www.adocia.com

MC Services AG
Adocia Press Relations Europe
Raimund Gabriel, Shaun Brown, Andreas Jungfer
[email protected]
Ph: +49 89 210 228 0

Source

ADOCIA

Provider

BusinessWire